4.82010.05% ( +0.440 )
Closed: Oct 2, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -0.32, above the reasonable range, cheaper than 2.63% of the time in the past 1 years, and the industry ranks 79/255, the industry Median -1.27.
-0.321xP/E
$4.82Stock price
$-15.01Earnings per share
-0.321xP/E
Stock price$4.82Earnings per share$-15.01
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.70x
- Typical range
- -1.18x–-0.53x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -54.04x | 149.86% | $56.42B |
BAYRYUSBayer | -24.62x | -- | $49.67B |
BAYZFUSBayer Aktiengesellschaft | -25.70x | -- | $51.86B |
VTRSUSViatris | -49.22x | 107.75% | $20.22B |
ELANUSElanco Animal Health | -55.59x | 129.36% | $11.06B |
AXSMUSAxsome Therap | -48.99x | 26.61% | $9.39B |
VREOFUSVIREO GROWTH INC | -134.31x | -- | $9.01B |
CURLFUSCuraleaf Holdings, Inc. | -146.39x | -- | $7.62B |
BLTEUSBelite Bio | -62.77x | 29.87% | $6.43B |
DFTXUSDefinium Therapeutics | -14.20x | 53.61% | $5.03B |
MANEUSVeraDermics | -46.78x | 97.44% | $4.88B |
EWTXUSEdgewise Therapeutics | -22.80x | 137.29% | $4.50B |
AMLXUSAmylyx Pharmaceuticals | -22.93x | 1.76% | $3.49B |
ELVNUSEnliven Therapeutics | -32.49x | 6.39% | $3.44B |
RGCUSRegencell Bioscience | -479.41x | -- | $3.38B |
TARSUSTarsus Pharmaceuticals | -68.93x | 205.82% | $3.20B |
MBXUSMBX Biosciences | -27.02x | 31.12% | $2.82B |
SUPNUSSupernus Pharma | -22.42x | 70.59% | $2.46B |
PHVSUSPharvaris BV | -11.04x | 9.52% | $2.19B |
BHCUSBausch Health | -1.98x | 307.94% | $2.17B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
